Oruka Therapeutics, Inc. Common Stock
Symbol: ORKA (NASDAQ)
Company Description:
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
- Today's Open: $26.81
- Today's High: $27.565
- Today's Low: $24.633
- Today's Volume: 55.29K
- Yesterday Close: $26.65
- Yesterday High: $27.66
- Yesterday Low: $25.11
- Yesterday Volume: 486.64K
- Last Min Volume: 232
- Last Min High: $27.345
- Last Min Low: $27.345
- Last Min VWAP: $27.345
- Name: Oruka Therapeutics, Inc. Common Stock
- Website: https://www.orukatx.com
- Listed Date: 2024-09-03
- Location: MENLO PARK, CA
- Market Status: Active
- CIK Number: 0000907654
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $1.32B
- Round Lot: 100
- Outstanding Shares: 48.38M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-10-17 | SCHEDULE 13G/A | View |
2025-10-14 | S-3/A | View |
2025-10-14 | S-3/A | View |
2025-10-03 | S-3 | View |
2025-10-03 | S-3 | View |
2025-09-24 | SCHEDULE 13G | View |
2025-09-22 | 424B3 | View |
2025-09-22 | 8-K | View |
2025-09-19 | SCHEDULE 13D/A | View |
2025-09-19 | 4 | View |
2025-08-11 | 424B3 | View |
2025-08-11 | 10-Q | View |
2025-07-17 | SCHEDULE 13G | View |
2025-07-01 | 4 | View |
2025-07-01 | 3 | View |
2025-07-01 | 8-K | View |
2025-06-03 | 4 | View |
2025-06-03 | 4 | View |
2025-06-03 | 4 | View |
2025-06-03 | 4 | View |